Currently, anti-HER2 agents are only administered to patients with a HER2-positive (HER2+) tumor (protein overexpression (3+) at the immunohistochemistry (IHC) or gene amplified by in situ hybridization (ISH)) [16,17]. The gene discussed is ERBB2; the disease is neoplasm.